Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

拓咨 - NMPA Drug Approval Details

Approvals/NMPA/Ixekizumab Injection

Approved

生物制品

Ixekizumab Injection

Eli Lilly and Company🇨🇳 National Medical Products Administration

Approval Date: Sep 10, 2024
Approval ID: 8bLXVtpUGIW
Company: Eli Lilly and Company
Type: 生物制品

Approval Details

Approval Id: 8bLXVtpUGIW
Approval Number: 国药准字SJ20190034
Generic Name: 依奇珠单抗注射液
Generic Name En: Ixekizumab Injection
Trade Name: 拓咨
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 80mg/mL(自动注射器)
Reg Date: 2024-09-10
Expired Date: 2029-05-08
Company Name: Eli Lilly and Company
Production Company Name: Eli Lilly and Company
Company Detail Path: /organization/eli-lilly-cdr-cad-hedged
Production Company Detail Path: /organization/eli-lilly-cdr-cad-hedged

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Sep 10, 2024

Approval ID

8bLXVtpUGIW

Type

生物制品

Back to NMPA Approvals